218 related articles for article (PubMed ID: 18991805)
1. Neurodegeneration and neuroprotective agents in multiple sclerosis.
Fong JS; Rae-Grant A; Huang D
Recent Pat CNS Drug Discov; 2008 Nov; 3(3):153-65. PubMed ID: 18991805
[TBL] [Abstract][Full Text] [Related]
2. [Neurodegeneration and neuroprotection in multiple sclerosis].
Davydovskaia MV; Boĭko AN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T
Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
[TBL] [Abstract][Full Text] [Related]
4. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
5. Advancing therapeutic options in multiple sclerosis with neuroprotective properties.
Stroet A; Linker RA; Gold R
J Neural Transm (Vienna); 2013 Sep; 120 Suppl 1():S49-53. PubMed ID: 23720188
[TBL] [Abstract][Full Text] [Related]
6. Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.
Bar-Or A; Rieckmann P; Traboulsee A; Yong VW
CNS Drugs; 2011 Sep; 25(9):783-99. PubMed ID: 21870889
[TBL] [Abstract][Full Text] [Related]
7. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Al-Izki S; Pryce G; Hankey DJ; Lidster K; von Kutzleben SM; Browne L; Clutterbuck L; Posada C; Edith Chan AW; Amor S; Perkins V; Gerritsen WH; Ummenthum K; Peferoen-Baert R; van der Valk P; Montoya A; Joel SP; Garthwaite J; Giovannoni G; Selwood DL; Baker D
Brain; 2014 Jan; 137(Pt 1):92-108. PubMed ID: 24287115
[TBL] [Abstract][Full Text] [Related]
8. MRI measures of neuroprotection and repair in multiple sclerosis.
Inglese M
J Neurol Sci; 2011 Dec; 311 Suppl 1():S16-23. PubMed ID: 22206761
[TBL] [Abstract][Full Text] [Related]
9. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
Rottlaender A; Kuerten S
Int J Mol Sci; 2015 Jul; 16(7):14850-65. PubMed ID: 26140377
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection in multiple sclerosis: a therapeutic approach.
Maghzi AH; Minagar A; Waubant E
CNS Drugs; 2013 Oct; 27(10):799-815. PubMed ID: 23955320
[TBL] [Abstract][Full Text] [Related]
11. MS as a gateway disease.
Lublin FD
J Neurol Sci; 2013 Oct; 333(1-2):73-5. PubMed ID: 23578792
[TBL] [Abstract][Full Text] [Related]
12. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
Recks MS; Bader J; Kaiser CC; Schroeter M; Fink GR; Addicks K; Kuerten S
Fortschr Neurol Psychiatr; 2011 Mar; 79(3):161-70. PubMed ID: 21394707
[TBL] [Abstract][Full Text] [Related]
13. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.
Zaveri MS; Conger A; Salter A; Frohman TC; Galetta SL; Markowitz CE; Jacobs DA; Cutter GR; Ying GS; Maguire MG; Calabresi PA; Balcer LJ; Frohman EM
Arch Neurol; 2008 Jul; 65(7):924-8. PubMed ID: 18625859
[TBL] [Abstract][Full Text] [Related]
14. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies.
van Noort JM; van den Elsen PJ; van Horssen J; Geurts JJ; van der Valk P; Amor S
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):68-81. PubMed ID: 21143143
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies in multiple sclerosis.
Farrell R; Heaney D; Giovannoni G
Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
[TBL] [Abstract][Full Text] [Related]
16. Ibudilast for the treatment of multiple sclerosis.
Goodman AD; Gyang T; Smith AD
Expert Opin Investig Drugs; 2016 Oct; 25(10):1231-7. PubMed ID: 27501293
[TBL] [Abstract][Full Text] [Related]
17. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine.
Kapoor R
J Neurol Sci; 2008 Nov; 274(1-2):54-6. PubMed ID: 18486153
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection and repair in multiple sclerosis.
Franklin RJ; ffrench-Constant C; Edgar JM; Smith KJ
Nat Rev Neurol; 2012 Nov; 8(11):624-34. PubMed ID: 23026979
[TBL] [Abstract][Full Text] [Related]
19. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets.
Aktas O; Waiczies S; Zipp F
J Neuroimmunol; 2007 Mar; 184(1-2):17-26. PubMed ID: 17222462
[TBL] [Abstract][Full Text] [Related]
20. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
Ziemssen T
J Neurol; 2005 Nov; 252 Suppl 5():v38-45. PubMed ID: 16254701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
